Literature DB >> 11745557

PMMA-based bioactive cement: effect of glass bead filler content and histological change with time.

Shuichi Shinzato1, Takashi Nakamura, Tadashi Kokubo, Yoshiro Kitamura.   

Abstract

A new bioactive bone cement (designated GBC), which is a polymethyl methacrylate (PMMA)-based composite consisting of bioactive glass beads as an inorganic filler and high molecular-weight PMMA as an organic matrix, has been developed. The purpose of the present study was to evaluate the effect of the filler content on the mechanical properties and osteoconductivity of GBC, to decide the most suitable filler proportion, and to evaluate the degree of cement degradation with time. The bioactive beads, consisting of MgO-CaO-SiO(2)-P(2)O(5)-CaF(2) glass, were added to the cement in various proportions (40-70 wt %). The bending strength of GBC did not differ among the proportions (approximately 136 MPa), but the elastic modulus of bending of GBC increased as the glass bead filler content increased (approximately 4.1-7.2 GPa). The all types of GBC were packed into the intramedullary canals of rat tibiae to evaluate osteoconductivity, as determined by an affinity index calculated as the length of bone in direct contact with the cement surface expressed as a percentage of the total length of the cement surface. Rats were sacrificed at 4, 8, 25, and 39 weeks after implantation, and the affinity index was calculated for each type of GBC at each time point. Histologically, new bone had formed along the surface of all types of GBC within 4 weeks, even in GBC containing only 40 wt % of glass beads. The affinity indices of GBC tended to increase as the proportion of glass bead filler increased and as the implantation period increased. In GBC containing 60 or 70 wt % of glass beads, significant rapid increases in the affinity indices were found from 4 to 8 weeks, and the high values (approximately 70%) were maintained up to 39 weeks. A sign of glass bead degradation was observed at the bone-cement interface in the rat tibiae at 39 weeks. We conclude that, when mechanical properties and osteoconductivity are both taken into consideration, GBC containing 60 or 70 wt % of glass beads is the most suitable formulation, but that further studies are needed to investigate and overcome the degradation. Copyright 2001 John Wiley & Sons, Inc. J Biomed Mater Res 59: 225-232, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11745557     DOI: 10.1002/jbm.1236

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  6 in total

1.  Optimization of the formulation and mechanical properties of starch based partially degradable bone cements.

Authors:  Luciano F Boesel; João F Mano; Rui L Reis
Journal:  J Mater Sci Mater Med       Date:  2004-01       Impact factor: 3.896

2.  Synthesis of bioactive PMMA bone cement via modification with methacryloxypropyltri-methoxysilane and calcium acetate.

Authors:  A Mori; C Ohtsuki; T Miyazaki; A Sugino; M Tanihara; K Kuramoto; A Osaka
Journal:  J Mater Sci Mater Med       Date:  2005-08       Impact factor: 3.896

3.  Hydrophilic matrices to be used as bioactive and degradable bone cements.

Authors:  Luciano F Boesel; Rui L Reis
Journal:  J Mater Sci Mater Med       Date:  2004-04       Impact factor: 3.896

4.  Injectable acrylic bone cements for vertebroplasty based on a radiopaque hydroxyapatite. Formulation and rheological behaviour.

Authors:  L Hernández; M Gurruchaga; I Goñi
Journal:  J Mater Sci Mater Med       Date:  2008-08-14       Impact factor: 3.896

5.  Osteoblast response to polymethyl methacrylate bioactive glass composite.

Authors:  M Hautamäki; V V Meretoja; R H Mattila; A J Aho; P K Vallittu
Journal:  J Mater Sci Mater Med       Date:  2010-02-17       Impact factor: 3.896

6.  Effect of pedicle screw augmentation with a self-curing elastomeric material under cranio-caudal cyclic loading-a cadaveric biomechanical study.

Authors:  Werner Schmoelz; Alexander Keiler; Marko Konschake; Richard A Lindtner; Alessandro Gasbarrini
Journal:  J Orthop Surg Res       Date:  2018-10-11       Impact factor: 2.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.